A former adversary of the DEA and HHS now shapes federal drug reform as Deputy General Counsel, steering executive orders and clinical access.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

A DEA administrative judge paused the cannabis rescheduling hearing to consider a GAO watchdog report on process gaps. A DEA response is due by October 13, adding delay and uncertainty.

A new GAO report says DEA and FDA lack clear drug-scheduling procedures just as an ALJ reviews moving cannabis to Schedule III and court fights continue.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

NORML argues federal health guidance and medical consensus point away from Schedule I. Here’s the science, policy context, and what DMV patients should watch.

HRSA logged 59 comments on training and outpatient delivery models for potential FDA‑approved psychedelic therapies. We unpack what’s being explored, plus why credentials, clinics, and costs matter.